pembrolizumab

pembrolizumab
Drug name	Pembrolizumab
Tradename	Keytruda
Routes of administration	Intravenous
Class	Monoclonal antibody, immune checkpoint inhibitor
Atc prefix	L01
Legal status	Prescription-only

pembrolizumab Pembrolizumab is a humanized monoclonal antibody used as an immune checkpoint inhibitor targeting the programmed death-1 receptor. Developed for oncology indications, it is administered intravenously and has become a cornerstone in the treatment of multiple malignancies. Its clinical adoption followed pivotal trials and regulatory approvals that involved collaborations among pharmaceutical companies, academic centers, and regulatory agencies.

Medical uses

Pembrolizumab is indicated for several cancers including melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, and urothelial carcinoma, and has been studied in other solid tumors. Clinical practice guidelines from organizations such as the National Comprehensive Cancer Network, European Society for Medical Oncology, and American Society of Clinical Oncology include pembrolizumab-based regimens for first-line or subsequent-line therapy in appropriate biomarker-selected populations. Its use is often guided by biomarker testing such as PD-L1 testing, tumor mutational burden, and mismatch repair status assessed by collaborations between pathology laboratories and oncology centers like Memorial Sloan Kettering Cancer Center and Mayo Clinic. Treatment decisions frequently involve multidisciplinary tumor boards across institutions including Johns Hopkins Hospital and MD Anderson Cancer Center.

Adverse effects

Immune-related adverse events associated with pembrolizumab include dermatitis, colitis, pneumonitis, hepatitis, and endocrinopathies such as thyroiditis and hypophysitis. Management of these events often follows protocols from organizations like the American Thyroid Association, Society for Immunotherapy of Cancer, and clinical pathways used at centers including Cleveland Clinic and Mount Sinai Health System. Severe toxicities may require corticosteroids or additional immunosuppression and coordination with specialists in pulmonology, gastroenterology, and endocrinology at hospitals such as Massachusetts General Hospital and Karolinska University Hospital.

Pharmacology

Pembrolizumab binds to the programmed death-1 receptor on T cells, blocking interaction with ligands expressed by tumor cells and antigen-presenting cells, thereby enhancing cytotoxic T cell activity. The mechanism of action was elucidated through basic research involving laboratories at institutions including Harvard Medical School, Stanford University School of Medicine, and the Dana-Farber Cancer Institute. Pharmacokinetic properties such as half-life, distribution, and clearance were characterized in clinical pharmacology studies often conducted in partnership with regulatory agencies like the Food and Drug Administration and the European Medicines Agency.

Clinical trials and approvals

Key randomized controlled trials and single-arm studies established efficacy in melanoma, non-small cell lung cancer, and other indications, with major publications appearing in journals frequented by researchers from Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Royal Marsden Hospital. Regulatory approvals were granted by agencies including the Food and Drug Administration, the European Medicines Agency, Health Canada, and regulatory bodies in countries such as Japan and Australia. Post-approval studies and real-world evidence initiatives have been sponsored or supported by collaborations among industry partners and academic networks like the American Association for Cancer Research and the European Organisation for Research and Treatment of Cancer.

History and development

The development of pembrolizumab involved discovery and translational work in academic laboratories, investments by biotechnology firms, and later acquisition and global development by a multinational pharmaceutical company. Key milestones include preclinical studies, phase I dose-escalation trials, and subsequent phase II and III trials designed and conducted at sites including Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Princess Margaret Cancer Centre. Regulatory submissions and accelerated approval pathways were influenced by precedents set in oncology drug development and interactions with agencies such as the Food and Drug Administration and European Medicines Agency.

Society and culture

Pembrolizumab has influenced public discourse on cancer therapy, pricing, and access, prompting debate among policymakers, patient advocacy organizations like American Cancer Society and Cancer Research UK, and payers including national health systems such as the National Health Service (England) and insurers in the United States. Its commercial success and patent landscape have engaged legal and economic discussions involving corporations, academic institutions, and competition authorities. Patient support groups and advocacy networks, including local chapters of Leukemia & Lymphoma Society and international consortia, have contributed to awareness, fundraising, and participation in clinical research.

Category:Antineoplastic drugs Category:Monoclonal antibodies